Efficacy and Safety of Ferric Carboxymaltose for Heart Failure with Iron Deficiency
Iron deficiency is prevalent in heart failure patients with reduced ejection fraction and is linked to poor outcomes. The HEART-FID trial investigates the impact of intravenous ferric carboxymaltose (FCM) on all-cause mortality, heart failure hospitalizations, and exercise capacity in chronic HFrEF
1 views • 17 slides
Optimizing Foundational Treatments for HFrEF: Guideline Recommendations and Implementation Strategies
Highlighting the current guideline recommendations for treating patients with Heart Failure with Reduced Ejection Fraction (HFrEF), this educational slide module emphasizes the importance of implementing the recommended therapies effectively. It covers the foundational treatments recommended by vari
0 views • 28 slides
Guideline Recommendations for SGLT2 Inhibitors in Heart Failure
This educational slide module provides an overview of the guideline recommendations for SGLT2 inhibitors in the treatment of heart failure, including HFrEF, HFmrEF, and HFpEF. It covers recommendations from AHA, ACC, HFSA, ESC, CCS, and CHFS guidelines, highlighting the role of SGLT2 inhibitors as a
0 views • 28 slides
Pharmacology of Heart Failure with Reduced Ejection Fraction (HFrEF)
Understanding the pharmacology of heart failure with reduced ejection fraction is crucial as it impacts millions of Americans and poses significant healthcare costs. The complex pathophysiology involves mechanisms like the Frank-Starling mechanism, alterations in myocyte regeneration, neurohumoral s
0 views • 44 slides